Chronic Myelogenous Leukemia (CML) Latest Advances

Single-cell disentangled representations for perturbation modeling and treatment effect estimation.

Journal: bioRxiv : the preprint server for biology

Published: December 15, 2025

Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!

Journal: Cancer

Published: December 10, 2025

Reply to "Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!"

Journal: Cancer

Published: December 10, 2025

Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.

Journal: Expert review of anticancer therapy

Published: December 10, 2025

Chronic myeloid leukemia presenting as B-lymphoblastic transformation after treatment for mucinous adenocarcinoma of unknown primary

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: December 07, 2025

Rebuilding the Marrow In Vitro: Translational Advances in the 3D Modeling of Blood Cancers.

Journal: Onco

Published: December 05, 2025

Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 03, 2025

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.

Journal: Blood

Published: November 27, 2025

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Journal: Journal of medical economics

Published: November 26, 2025

Influence of Oxidation Resistance 1 on disease progression in chronic myeloid leukemia.

Journal: JCI insight

Published: November 25, 2025

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.

Journal: Leukemia & lymphoma

Published: November 21, 2025

Filters

Single-cell disentangled representations for perturbation modeling and treatment effect estimation.

Single-cell disentangled representations for perturbation modeling and treatment effect estimation.

Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!

Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!

Reply to "Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!"

Reply to "Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!"

Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.

Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.

Chronic myeloid leukemia presenting as B-lymphoblastic transformation after treatment for mucinous adenocarcinoma of unknown primary

Chronic myeloid leukemia presenting as B-lymphoblastic transformation after treatment for mucinous adenocarcinoma of unknown primary

Rebuilding the Marrow In Vitro: Translational Advances in the 3D Modeling of Blood Cancers.

Rebuilding the Marrow In Vitro: Translational Advances in the 3D Modeling of Blood Cancers.

Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation

Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.

Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Influence of Oxidation Resistance 1 on disease progression in chronic myeloid leukemia.

Influence of Oxidation Resistance 1 on disease progression in chronic myeloid leukemia.

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.

Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.